A clinical trial to investigate the clinical performance and safety of Hydroxypropyl-Beta-Cyclodextrin 10% w/v Eye drops In the treAtment of dry eye disease

Warneford Healthcare Ltd.0 个研究点目标入组 11 人开始时间: 2019年3月4日最近更新: 2021年8月24日

适应症

试验速览

暂无简介。

•1. Current smoker.
•2. Known to suffer from an allergy or hypersensitivity to any of the components within the medical device.
•3. Taking any other eye drops for dry eye.
•4. Taking any other eye drops containing cyclodextrin.
•5. Has used contact lenses within the last 4-7 days.
•6. Has dry eye secondary to eyelid malposition, corneal dystrophy, ocular neoplasia, filamentous keratitis, corneal neovascularisation or orbital radiotherapy, or a history of ocular disease including traumatism, infection, inflammation, allergy, or herpes within the last 3 months.
•7. History of inflammatory corneal ulcer or uveitis within the last 12 months.
•8. Has allergic rhinitis that is current or susceptible to reactivation during the study
•9. Has had cataract or corneal surgery in the last 12 months.
•10. Currently participating in any other clinical trial or has participated in another clinical trial within 3 months prior to the screening/baseline visit.
•11. Not physically able to perform study procedures.
•12. History of drug/alcohol abuse, mental dysfunction or other factors limiting their ability to cooperate fully.
•13. Has any other condition, which in the opinion of the investigator, would make the subject not a suitable candidate for the study.

发起方

Warneford Healthcare Ltd.